NCT03402152 — "NRX101 Glx Biomarker Validation Study" trial site landscape

Public-registry site landscape for NCT03402152, “NRX101 Glx Biomarker Validation Study”, a Bipolar Depression study sponsored by NeuroRx, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT03402152 (registry record)
Study title	NRX101 Glx Biomarker Validation Study
Official title	Validation of the Glx Biomarker for Treatment of Moderate Bipolar Depression With NRX-101
Sponsor	NeuroRx, Inc.
Condition(s)	Bipolar Depression; Suicidal Ideation
Phase	PHASE2 / PHASE3
Listed sites	1
Site countries	United States

Patient-friendly overview of this study: eichor.com/study/NCT03402152.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT03402152 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Related trials

Other Bipolar Depression trials

← Eichor home · All tracked trials · Bipolar Depression studies · Weekly briefs

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →